NVS on NYSE

Novartis

Logo: Novartis, Public domain, via Wikimedia Commons⁴

Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.³ From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

$14.0BNet income, fiscal 2025⁵

1996Founded¹

Compare with another stock.

TickerNVS on NYSE¹
Industrychemical industry, pharmaceutical industry¹
HeadquartersBasel¹
Websitewww.novartis.com
Legal formAktiengesellschaft¹
Listed onSwiss Stock Exchange (NOVN), New York Stock Exchange (NVS)¹
Incorporated inSwitzerland⁶
Business addressLichtstrasse 35, Basel, V8 Ch 4056⁶
Filer categoryLarge accelerated filer⁶

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

30.0%Return on equity⁵

$17.6BFree cash flow⁵

Financial statements

Gross profit⁸⁹¹⁰¹¹¹²⁵$43.0B in 2025+36% since 2018

Operating income⁸⁹¹⁰¹¹¹²⁵$17.6B in 2025+110% since 2018

Net income⁸⁹¹⁰¹¹¹²⁵$14.0B in 2025+11% since 2018

Every line of the income statement in the latest annual report, as filed.⁵

Period ending	2025-12-31	2024-12-31	2023-12-31
Net sales from continuing operations	$54.5B	$50.3B	$45.4B
Other revenues	$2.1B	$1.4B	$1.2B
Cost of goods sold	-$13.7B	-$12.8B	-$12.5B
Gross profit from continuing operations	$43.0B	$38.9B	$34.2B
Selling, general and administration	-$13.2B	-$12.6B	-$12.5B
Research and development	-$11.2B	-$10.0B	-$11.4B
Other income	$1.5B	$1.2B	$1.8B
Other expense	-$2.3B	-$2.9B	-$2.3B
Operating income from continuing operations	$17.6B	$14.5B	$9.8B
Loss from associated companies	-$12.0M	-$38.0M	-$13.0M
Interest expense	-$1.1B	-$1.0B	-$855.0M
Other financial income and expense	-$136.0M	$140.0M	$222.0M
Income before taxes from continuing operations	$16.4B	$13.6B	$9.1B
Income taxes	-$2.4B	-$1.7B	-$551.0M
Net income from continuing operations	$14.0B	$11.9B	$8.6B
Net income from discontinued operations before gain on distribution			$422.0M
Gain on distribution of Sandoz Group AG to Novartis AG shareholders			$5.9B
Net income from discontinued operations			$6.3B
Net income	$14.0B	$11.9B	$14.9B
Shareholders of Novartis AG	$14.0B	$11.9B	$14.8B
Non-controlling interests	-$17.0M	-$2.0M	$4.0M
Basic earnings (loss) per share from continuing operations	$7.21	$5.92	$4.13
Basic earnings (loss) per share from discontinued operations			$3.02
Basic earnings per share	$7.21	$5.92	$7.15
Diluted earnings (loss) per share from continuing operations	$7.15	$5.87	$4.10
Diluted earnings (loss) per share from discontinued operations			$3.00
Diluted earnings per share	$7.15	$5.87	$7.10

Total assets¹³⁸⁹¹⁰¹¹¹²⁵$110.9B in 2025−24% since 2018

Total liabilities¹³⁸⁹¹⁰¹¹¹²⁵$64.4B in 2025−4% since 2018

Shareholders’ equity⁸⁹¹⁰¹²⁵$46.5B in 2025−41% since 2018

Cash⁹¹⁰¹¹¹²⁵$11.4B in 2025−14% since 2018

Every line of the balance sheet in the latest annual report, as filed.⁵

Period ending	2025-12-31	2024-12-31	2023-12-31
Property, plant and equipment	$10.8B	$9.5B	$9.5B
Right-of-use assets	$1.6B	$1.4B	$1.4B
Goodwill	$25.6B	$24.8B
Intangible assets other than goodwill	$29.4B	$26.9B
Investments in associated companies	$98.0M	$119.0M
Deferred tax assets	$5.4B	$4.4B
Financial assets	$2.3B	$2.0B
Other non-current assets	$5.3B	$3.5B
Total non-current assets	$80.5B	$72.5B
Inventories	$6.3B	$5.7B
Trade receivables	$8.9B	$7.4B
Income tax receivables	$205.0M	$133.0M
Marketable securities, time deposits and derivative financial instruments	$155.0M	$2.0B
Cash and cash equivalents	$11.4B	$11.5B	$13.4B
Other current assets	$3.5B	$3.0B
Total current assets	$30.5B	$29.7B
Total assets	$110.9B	$102.2B
Share capital	$766.0M	$793.0M	$825.0M
Treasury shares	-$50.0M	-$53.0M	-$41.0M
Reserves	$45.4B	$43.3B
Equity attributable to Novartis AG shareholders	$46.1B	$44.0B
Non-controlling interests	$419.0M	$80.0M
Total equity	$46.5B	$44.1B	$46.8B
Financial debts	$27.9B	$21.4B
Lease liabilities	$1.7B	$1.6B
Deferred tax liabilities	$3.4B	$2.4B
Provisions and other non-current liabilities	$4.1B	$4.1B
Total non-current liabilities	$37.1B	$29.4B
Trade payables	$4.5B	$4.6B
Financial debts and derivative financial instruments	$5.6B	$8.2B
Lease liabilities	$263.0M	$235.0M
Current income tax liabilities	$2.0B	$1.6B
Provisions and other current liabilities	$15.0B	$14.1B
Total current liabilities	$27.3B	$28.7B
Total liabilities	$64.4B	$58.1B
Total equity and liabilities	$110.9B	$102.2B

Cash from operations⁸⁹¹⁰¹¹¹²⁵$19.1B in 2025+34% since 2018

Capital spending⁸⁹¹⁰¹¹¹²⁵$1.5B in 2025+23% since 2018

Free cash flow⁸⁹¹⁰¹¹¹²⁵$17.6B in 2025+35% since 2018

Every line of the cash flow in the latest annual report, as filed.⁵

Period ending	2025-12-31	2024-12-31	2023-12-31
Net income from continuing operations	$14.0B	$11.9B	$8.6B
Reversal of non-cash items and other adjustments	$11.2B	$10.2B	$10.4B
Dividends received from associated companies and others	$1.0M	$1.0M	$2.0M
Interest received	$310.0M	$489.0M	$645.0M
Interest paid	-$981.0M	-$855.0M	-$751.0M
Other financial receipts	$266.0M		$90.0M
Other financial payments	-$26.0M	-$116.0M	-$17.0M
Income taxes paid	-$2.6B	-$2.3B	-$2.8B
Net cash flows from operating activities from continuing operations before working capital and provision changes	$22.2B	$19.4B	$16.1B
Payments out of provisions and other net cash movements in non-current liabilities	-$1.5B	-$1.1B	-$1.5B
Changes in working capital and other operating cash flow items	-$1.6B	-$706.0M	-$369.0M
Net cash flows from operating activities from continuing operations	$19.1B	$17.6B	$14.2B
Net cash flows from operating activities from discontinued operations			$238.0M
Total net cash flows from operating activities	$19.1B	$17.6B	$14.5B
Purchases of property, plant and equipment	-$1.5B	-$1.4B	-$1.1B
Proceeds from sale of property, plant and equipment	$13.0M	$86.0M	$237.0M
Purchases of intangible assets	-$2.4B	-$2.4B	-$1.7B
Proceeds from sale of intangible assets	$164.0M	$80.0M	$2.0B
Purchases of financial assets	-$116.0M	-$193.0M	-$106.0M
Proceeds from sale of financial assets	$209.0M	$957.0M	$348.0M
Acquisitions of businesses	-$147.0M	-$4.0B	-$3.6B
Acquisitions applying the optional concentration test	-$2.8B
Divestments of businesses, net	-$88.0M	$107.0M	$3.0M
Investments in time deposits and marketable securities	-$187.0M	-$3.5B	-$641.0M
Proceeds from time deposits and from sale of marketable securities and commodities	$2.0B	$2.7B	$11.2B
Other investing cash flows, net	-$24.0M	-$7.0M	-$11.0M
Net cash flows (used in)/(from) investing activities from continuing operations	-$4.9B	-$7.5B	$6.7B
Net cash flows used in investing activities from discontinued operations			-$1.1B
Total net cash flows (used in)/from investing activities	-$4.9B	-$7.5B	$5.6B
Dividends paid to shareholders of Novartis AG	-$7.8B	-$7.6B	-$7.3B
Purchases of treasury shares	-$9.2B	-$8.3B	-$8.7B
Proceeds from exercised options and other treasury share transactions, net	$27.0M	$30.0M	$153.0M
Proceeds from non-current financial debts	$6.1B	$6.1B
Repayments of the current portion of non-current financial debts	-$3.4B	-$2.2B	-$2.2B
Change in current financial debts	$5.0M	$958.0M	$546.0M
Repayments of other current financial debts		-$289.0M
Payments of lease liabilities	-$281.0M	-$262.0M	-$258.0M
Payments from changes in ownership interests in consolidated subsidiaries	-$91.0M	-$293.0M
Other financing cash flows, net	-$203.0M	$86.0M	$192.0M
Net cash flows used in financing activities from continuing operations	-$14.9B	-$11.7B	-$17.6B
Net cash flows from financing activities from discontinued operations			$3.3B
Total net cash flows used in financing activities	-$14.9B	-$11.7B	-$14.3B
Net change in cash and cash equivalents before effect of exchange rate changes	-$600.0M	-$1.6B	$5.8B
Effect of exchange rate changes on cash and cash equivalents	$576.0M	-$298.0M	$100.0M
Net change in cash and cash equivalents	-$24.0M	-$1.9B	$5.9B

Compare Novartis with another company

How it started

History

Novartis was created in March 1996 and began operations on 20 December from the merger of Ciba-Geigy and Sandoz Laboratories, both Swiss companies.

Ciba-Geigy

Ciba-Geigy was formed in 1970 by the merger of J. R. Geigy Ltd (founded in Basel in 1857) and CIBA (founded in Basel in 1859).

Ciba began in 1859, when Alexander Clavel (1805–1873) took up the production of fuchsine in his factory for silk-dyeing works in Basel. By 1873, he sold his dye factory to the company Bindschedler and Busch. In 1884, Bindschedler and Busch was transformed into a joint-stock company named "Gesellschaft für Chemische Industrie Basel" (Company for Chemical Industry Basel). The acronym, CIBA, was adopted as the company's name in 1945.

The foundation for Geigy was established in 1857, when Johann Rudolf Geigy-Merian (1830–1917) and Johann Muller-Pack acquired a site in Basel, where they built a dyewood mill and a dye extraction plant. Two years later, they began the production of synthetic fuchsine. In 1901, they formed the public limited company Geigy, and the name of the company was changed to J. R. Geigy Ltd in 1914.

From Wikipedia’s article on Novartis, shared under CC BY-SA 4.0.³

Leadership

Who has led Novartis, and when. Pick a name to see everywhere that person has worked.

Chief executive

1995200020052010201520202025

Chief executive officerVasant Narasimhan Sep 5, 2017 to now¹
Chief executive officerJoseph Jimenez 2010 to Sep 5, 2017¹
Chief executive officerDan Vasella until 2010¹

Board members and other officers (2)

Board memberBülent Kızıltan 2020 to now¹
Board memberYves P Auberson Dec 1, 1992 to now¹

Products and brands

Diclofenac
medication

Listed on Wikidata.¹

Subsidiaries and ownership

Subsidiaries

Alcon
Avidity Biosciences
Chiron Corporation
Ciba Vision
Medicines Company (United States)
Novartis
Novartis (Austria)
Novartis (Canada)
Novartis (China)
Novartis (France)
Novartis (Germany)
Novartis (Italy)
Novartis (Japan)
Novartis (Mexico)
Novartis (Netherlands)
Novartis (Singapore)
Novartis (Slovenia)
Novartis (United Kingdom)
Novartis Baltics, SIA
Novartis Gene Therapies
Novartis Healthcare (India)
Sandoz

Also owns

Lab'O

From Wikidata.¹

Acquisitions

Succeeded Ciba-Geigy¹

Timeline

Sep 5, 2017New chief executive Vasant Narasimhan becomes CEO¹
2010New chief executive Joseph Jimenez becomes CEO¹
May 11, 2000Went public Listed on NYSE¹
1996Founded Founded¹

Recent filings

Sep 8, 20266-K
Sep 4, 20266-K
Sep 1, 20266-K
Jul 21, 20266-K
Jun 11, 20266-K
Apr 30, 2026144
Apr 28, 20266-K
Mar 18, 20266-K
Mar 17, 2026FWP
Mar 17, 2026424B5
Mar 16, 2026424B5
Feb 12, 2026144
Feb 9, 2026144
Feb 4, 202620-F
Feb 4, 2026IRANNOTICE

Every filing from the last three years, summarized. The full record is on SEC EDGAR.²

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataNovartis on Wikidata
2
SEC EDGARNovartis filings on SEC EDGAR
3
WikipediaNovartis on Wikipedia
4
Wikimedia CommonsNovartis logo by Novartis, Public domain
5
SEC EDGARNovartis 10-K for fiscal 2025
6
SEC EDGARNovartis filings on SEC EDGAR
7
Wikimedia CommonsNovartis photo by Alexandre Prevot from Nancy, France, CC BY-SA 2.0
8
SEC EDGARNovartis 10-K for fiscal 2018
9
SEC EDGARNovartis 10-K for fiscal 2019
10
SEC EDGARNovartis 10-K for fiscal 2020
11
SEC EDGARNovartis 10-K for fiscal 2021
12
SEC EDGARNovartis 10-K for fiscal 2022
13
SEC EDGARNovartis 10-K for fiscal 2018